| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 87 | 2024 | 2493 | 5.800 |
Why?
|
| Delirium | 37 | 2024 | 1694 | 2.810 |
Why?
|
| Androgens | 31 | 2023 | 1285 | 2.640 |
Why?
|
| Hypogonadism | 16 | 2024 | 805 | 2.420 |
Why?
|
| Mobility Limitation | 25 | 2023 | 409 | 2.330 |
Why?
|
| Sex Hormone-Binding Globulin | 21 | 2024 | 554 | 2.250 |
Why?
|
| Muscle Strength | 18 | 2023 | 641 | 1.760 |
Why?
|
| Sarcopenia | 11 | 2021 | 376 | 1.670 |
Why?
|
| Erectile Dysfunction | 12 | 2024 | 445 | 1.590 |
Why?
|
| Accidental Falls | 16 | 2021 | 1081 | 1.580 |
Why?
|
| Body Composition | 25 | 2024 | 2455 | 1.540 |
Why?
|
| Hand Strength | 12 | 2020 | 465 | 1.530 |
Why?
|
| Aging | 35 | 2024 | 8761 | 1.490 |
Why?
|
| Estradiol | 16 | 2024 | 1949 | 1.420 |
Why?
|
| Hormone Replacement Therapy | 15 | 2024 | 756 | 1.410 |
Why?
|
| Estrone | 9 | 2018 | 234 | 1.390 |
Why?
|
| Geriatric Assessment | 16 | 2023 | 1422 | 1.060 |
Why?
|
| Androgen Antagonists | 7 | 2024 | 1418 | 1.020 |
Why?
|
| Walking | 9 | 2021 | 1202 | 1.000 |
Why?
|
| Gait | 13 | 2023 | 822 | 0.960 |
Why?
|
| Aged | 184 | 2024 | 171520 | 0.900 |
Why?
|
| Muscle, Skeletal | 15 | 2024 | 4984 | 0.870 |
Why?
|
| Postural Balance | 10 | 2020 | 638 | 0.860 |
Why?
|
| Independent Living | 18 | 2023 | 580 | 0.850 |
Why?
|
| Frail Elderly | 5 | 2023 | 774 | 0.740 |
Why?
|
| Recovery of Function | 6 | 2020 | 2994 | 0.710 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2021 | 242 | 0.690 |
Why?
|
| Muscle Weakness | 6 | 2020 | 415 | 0.680 |
Why?
|
| Bone Density | 14 | 2018 | 3561 | 0.670 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 4 | 2013 | 104 | 0.650 |
Why?
|
| Male | 199 | 2024 | 364781 | 0.650 |
Why?
|
| Prediabetic State | 1 | 2024 | 548 | 0.600 |
Why?
|
| Femur | 3 | 2008 | 1311 | 0.580 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2017 | 43 | 0.560 |
Why?
|
| Gonadal Steroid Hormones | 5 | 2023 | 708 | 0.550 |
Why?
|
| Postoperative Complications | 23 | 2024 | 15880 | 0.540 |
Why?
|
| Insulin Resistance | 8 | 2024 | 3974 | 0.540 |
Why?
|
| Dementia | 7 | 2022 | 2723 | 0.540 |
Why?
|
| Aged, 80 and over | 66 | 2024 | 59680 | 0.530 |
Why?
|
| Humans | 241 | 2024 | 768451 | 0.520 |
Why?
|
| Patient Readmission | 6 | 2021 | 3308 | 0.510 |
Why?
|
| Luteinizing Hormone | 8 | 2024 | 821 | 0.490 |
Why?
|
| Prospective Studies | 55 | 2024 | 54914 | 0.480 |
Why?
|
| Hip Fractures | 4 | 2020 | 996 | 0.470 |
Why?
|
| Prostatic Neoplasms | 8 | 2024 | 11206 | 0.470 |
Why?
|
| Double-Blind Method | 32 | 2024 | 12450 | 0.450 |
Why?
|
| Exercise | 8 | 2020 | 5940 | 0.450 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 2018 | 692 | 0.450 |
Why?
|
| Genes, Y-Linked | 1 | 2013 | 12 | 0.440 |
Why?
|
| Cross-Sectional Studies | 40 | 2024 | 26351 | 0.440 |
Why?
|
| Longitudinal Studies | 23 | 2023 | 14766 | 0.440 |
Why?
|
| Pacemaker, Artificial | 2 | 2017 | 828 | 0.430 |
Why?
|
| Cerebrovascular Circulation | 4 | 2017 | 2737 | 0.430 |
Why?
|
| Malnutrition | 1 | 2020 | 632 | 0.430 |
Why?
|
| Middle Aged | 100 | 2024 | 223418 | 0.430 |
Why?
|
| Research Design | 8 | 2024 | 6217 | 0.410 |
Why?
|
| Activities of Daily Living | 8 | 2023 | 2433 | 0.400 |
Why?
|
| Kyphosis | 4 | 2019 | 253 | 0.390 |
Why?
|
| Analgesics, Opioid | 8 | 2022 | 3837 | 0.390 |
Why?
|
| Absorptiometry, Photon | 13 | 2021 | 1749 | 0.390 |
Why?
|
| Andropause | 2 | 2008 | 8 | 0.380 |
Why?
|
| Motor Activity | 2 | 2012 | 2722 | 0.380 |
Why?
|
| Dietary Proteins | 5 | 2021 | 960 | 0.370 |
Why?
|
| Models, Statistical | 3 | 2020 | 5103 | 0.370 |
Why?
|
| Dihydrotestosterone | 4 | 2024 | 195 | 0.370 |
Why?
|
| Ataxia | 3 | 2017 | 307 | 0.350 |
Why?
|
| Retinoscopy | 1 | 2010 | 27 | 0.350 |
Why?
|
| Dietary Supplements | 7 | 2020 | 3445 | 0.350 |
Why?
|
| Chromatography, Liquid | 6 | 2013 | 998 | 0.340 |
Why?
|
| Cardiovascular Diseases | 18 | 2024 | 15638 | 0.340 |
Why?
|
| Body Mass Index | 19 | 2024 | 13030 | 0.330 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 2258 | 0.330 |
Why?
|
| Female | 109 | 2024 | 396943 | 0.320 |
Why?
|
| Thoracic Vertebrae | 3 | 2019 | 613 | 0.320 |
Why?
|
| Refraction, Ocular | 1 | 2010 | 186 | 0.310 |
Why?
|
| Consensus | 5 | 2020 | 3207 | 0.300 |
Why?
|
| Refractive Errors | 1 | 2010 | 148 | 0.300 |
Why?
|
| Weight Loss | 3 | 2016 | 2710 | 0.300 |
Why?
|
| Life Style | 6 | 2024 | 3929 | 0.290 |
Why?
|
| Boston | 18 | 2023 | 9361 | 0.290 |
Why?
|
| Alzheimer Disease | 7 | 2024 | 8721 | 0.290 |
Why?
|
| Cohort Studies | 27 | 2024 | 41797 | 0.290 |
Why?
|
| Tandem Mass Spectrometry | 6 | 2013 | 1197 | 0.290 |
Why?
|
| Gastric Bypass | 1 | 2016 | 829 | 0.290 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 1498 | 0.280 |
Why?
|
| Cognition | 12 | 2023 | 7066 | 0.280 |
Why?
|
| Hysterectomy | 3 | 2019 | 863 | 0.280 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 2028 | 0.280 |
Why?
|
| Intra-Abdominal Fat | 2 | 2023 | 623 | 0.280 |
Why?
|
| Adult | 71 | 2024 | 223542 | 0.270 |
Why?
|
| Sulfones | 3 | 2013 | 448 | 0.260 |
Why?
|
| Femur Neck | 5 | 2018 | 319 | 0.260 |
Why?
|
| Massachusetts | 11 | 2022 | 8908 | 0.260 |
Why?
|
| Cognition Disorders | 5 | 2018 | 3985 | 0.250 |
Why?
|
| Libido | 1 | 2006 | 124 | 0.250 |
Why?
|
| Risk Factors | 38 | 2024 | 74915 | 0.250 |
Why?
|
| Fontan Procedure | 4 | 2012 | 805 | 0.250 |
Why?
|
| Health Status | 8 | 2018 | 4096 | 0.250 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 1309 | 0.240 |
Why?
|
| Tai Ji | 2 | 2019 | 291 | 0.240 |
Why?
|
| Age Factors | 16 | 2024 | 18478 | 0.230 |
Why?
|
| Quality of Life | 13 | 2023 | 13497 | 0.230 |
Why?
|
| Remission, Spontaneous | 3 | 2011 | 385 | 0.230 |
Why?
|
| Geriatric Nursing | 2 | 2021 | 39 | 0.220 |
Why?
|
| Leg Injuries | 4 | 2007 | 180 | 0.220 |
Why?
|
| Physicians | 1 | 2022 | 4615 | 0.220 |
Why?
|
| Disability Evaluation | 4 | 2020 | 1839 | 0.220 |
Why?
|
| Interleukin-6 | 3 | 2024 | 3234 | 0.210 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2016 | 112 | 0.210 |
Why?
|
| Atrophy | 3 | 2024 | 1648 | 0.210 |
Why?
|
| Erythropoietin | 3 | 2018 | 719 | 0.210 |
Why?
|
| Prevalence | 12 | 2020 | 15880 | 0.210 |
Why?
|
| Biostatistics | 1 | 2024 | 165 | 0.210 |
Why?
|
| Incidence | 14 | 2024 | 21552 | 0.210 |
Why?
|
| Urinary Retention | 1 | 2023 | 106 | 0.210 |
Why?
|
| Socioeconomic Factors | 8 | 2024 | 7863 | 0.210 |
Why?
|
| Fluoroimmunoassay | 2 | 2013 | 30 | 0.210 |
Why?
|
| Severity of Illness Index | 12 | 2023 | 15965 | 0.210 |
Why?
|
| Erythropoiesis | 2 | 2018 | 694 | 0.200 |
Why?
|
| Hospitalization | 11 | 2022 | 10845 | 0.200 |
Why?
|
| Fractures, Bone | 4 | 2022 | 2063 | 0.200 |
Why?
|
| Exercise Test | 5 | 2020 | 2186 | 0.200 |
Why?
|
| Psychometrics | 4 | 2022 | 3072 | 0.200 |
Why?
|
| Adipose Tissue | 3 | 2023 | 3335 | 0.200 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 39430 | 0.190 |
Why?
|
| Administration, Cutaneous | 7 | 2020 | 716 | 0.190 |
Why?
|
| Oxygen Consumption | 3 | 2018 | 1882 | 0.190 |
Why?
|
| Liver | 4 | 2024 | 7575 | 0.190 |
Why?
|
| Ergocalciferols | 2 | 2013 | 110 | 0.190 |
Why?
|
| Logistic Models | 12 | 2020 | 13324 | 0.190 |
Why?
|
| Health Education | 2 | 2019 | 1059 | 0.190 |
Why?
|
| Polycythemia | 2 | 2013 | 124 | 0.180 |
Why?
|
| Reference Values | 7 | 2017 | 4941 | 0.180 |
Why?
|
| Depression | 8 | 2024 | 8235 | 0.180 |
Why?
|
| Loneliness | 1 | 2023 | 207 | 0.180 |
Why?
|
| Physical Fitness | 3 | 2020 | 744 | 0.180 |
Why?
|
| Estrogens | 3 | 2012 | 1531 | 0.180 |
Why?
|
| Lower Extremity | 3 | 2019 | 1214 | 0.180 |
Why?
|
| C-Reactive Protein | 3 | 2024 | 3854 | 0.180 |
Why?
|
| Vitamin D | 6 | 2018 | 3311 | 0.170 |
Why?
|
| Cerebral Cortex | 3 | 2024 | 5827 | 0.170 |
Why?
|
| Affect | 3 | 2018 | 1498 | 0.170 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 12096 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 10358 | 0.170 |
Why?
|
| Geriatrics | 1 | 2024 | 390 | 0.170 |
Why?
|
| Confidence Intervals | 6 | 2011 | 2932 | 0.170 |
Why?
|
| Baltimore | 1 | 2020 | 234 | 0.170 |
Why?
|
| Aspirin | 2 | 2022 | 3139 | 0.170 |
Why?
|
| Gels | 5 | 2023 | 421 | 0.170 |
Why?
|
| Health Surveys | 7 | 2020 | 4056 | 0.170 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 4249 | 0.170 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2013 | 353 | 0.160 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2017 | 74 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2019 | 10784 | 0.160 |
Why?
|
| Nurse's Role | 1 | 2020 | 188 | 0.160 |
Why?
|
| Risk Assessment | 14 | 2021 | 24311 | 0.160 |
Why?
|
| Bone Remodeling | 2 | 2017 | 583 | 0.160 |
Why?
|
| Treatment Outcome | 24 | 2024 | 65409 | 0.160 |
Why?
|
| Hydrocortisone | 1 | 2007 | 1836 | 0.160 |
Why?
|
| Health Services for the Aged | 1 | 2021 | 258 | 0.160 |
Why?
|
| Leuprolide | 2 | 2018 | 313 | 0.160 |
Why?
|
| Placebos | 5 | 2018 | 1668 | 0.160 |
Why?
|
| Medication Reconciliation | 1 | 2020 | 153 | 0.160 |
Why?
|
| Osteoporosis | 3 | 2018 | 1606 | 0.160 |
Why?
|
| Leg | 1 | 2023 | 1089 | 0.150 |
Why?
|
| Nursing Homes | 3 | 2022 | 1084 | 0.150 |
Why?
|
| Piperazines | 3 | 2013 | 2546 | 0.150 |
Why?
|
| Lumbar Vertebrae | 4 | 2019 | 1885 | 0.150 |
Why?
|
| Radius | 3 | 2011 | 443 | 0.150 |
Why?
|
| Eunuchism | 1 | 2017 | 19 | 0.150 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 1084 | 0.140 |
Why?
|
| Aromatase | 1 | 2018 | 147 | 0.140 |
Why?
|
| Europe | 2 | 2017 | 3439 | 0.140 |
Why?
|
| Agrin | 1 | 2017 | 75 | 0.140 |
Why?
|
| Disease Progression | 8 | 2018 | 13655 | 0.140 |
Why?
|
| Neuropsychological Tests | 7 | 2020 | 7134 | 0.140 |
Why?
|
| Confusion | 2 | 2016 | 278 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2020 | 304 | 0.140 |
Why?
|
| Pharmacoepidemiology | 1 | 2020 | 352 | 0.140 |
Why?
|
| Ankle | 1 | 2020 | 354 | 0.140 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 15460 | 0.140 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2018 | 294 | 0.140 |
Why?
|
| Wounds and Injuries | 3 | 2018 | 2518 | 0.130 |
Why?
|
| Reference Standards | 2 | 2017 | 1015 | 0.130 |
Why?
|
| Gonadotrophs | 1 | 2016 | 19 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2023 | 1536 | 0.130 |
Why?
|
| Long-Term Care | 1 | 2020 | 633 | 0.130 |
Why?
|
| Prostatectomy | 1 | 2024 | 1840 | 0.130 |
Why?
|
| Public Housing | 1 | 2017 | 140 | 0.130 |
Why?
|
| Spinal Curvatures | 1 | 2016 | 73 | 0.130 |
Why?
|
| Cause of Death | 2 | 2024 | 3727 | 0.130 |
Why?
|
| Pain Perception | 1 | 2017 | 198 | 0.130 |
Why?
|
| Finasteride | 1 | 2016 | 86 | 0.130 |
Why?
|
| Mental Health | 3 | 2023 | 3271 | 0.130 |
Why?
|
| Endocrine System Diseases | 2 | 2008 | 250 | 0.130 |
Why?
|
| Reproducibility of Results | 8 | 2022 | 20231 | 0.120 |
Why?
|
| Time Factors | 13 | 2024 | 40271 | 0.120 |
Why?
|
| Motor Skills | 1 | 2018 | 522 | 0.120 |
Why?
|
| Mortality | 3 | 2020 | 2917 | 0.120 |
Why?
|
| Resistance Training | 1 | 2017 | 199 | 0.120 |
Why?
|
| Inflammation | 6 | 2024 | 10865 | 0.120 |
Why?
|
| Blood Chemical Analysis | 1 | 2017 | 436 | 0.120 |
Why?
|
| Accidents, Home | 1 | 2015 | 73 | 0.120 |
Why?
|
| Craniocerebral Trauma | 1 | 2019 | 496 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
| Videoconferencing | 1 | 2017 | 207 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 36840 | 0.120 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2016 | 191 | 0.120 |
Why?
|
| Heart Defects, Congenital | 4 | 2012 | 4713 | 0.120 |
Why?
|
| Sensory Aids | 1 | 2014 | 40 | 0.120 |
Why?
|
| Institutionalization | 1 | 2015 | 108 | 0.120 |
Why?
|
| United States | 18 | 2022 | 73121 | 0.120 |
Why?
|
| Inheritance Patterns | 1 | 2016 | 341 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2021 | 838 | 0.110 |
Why?
|
| Orthopedic Procedures | 3 | 2020 | 1280 | 0.110 |
Why?
|
| Shoes | 1 | 2014 | 92 | 0.110 |
Why?
|
| Patients | 1 | 2020 | 909 | 0.110 |
Why?
|
| Vascular Resistance | 1 | 2017 | 941 | 0.110 |
Why?
|
| Anemia | 1 | 2023 | 1521 | 0.110 |
Why?
|
| Football | 1 | 2019 | 507 | 0.110 |
Why?
|
| Motor Cortex | 1 | 2021 | 1015 | 0.110 |
Why?
|
| Health Services Research | 1 | 2021 | 1815 | 0.110 |
Why?
|
| Diet Records | 1 | 2015 | 427 | 0.110 |
Why?
|
| Catastrophization | 1 | 2017 | 349 | 0.110 |
Why?
|
| Spleen | 2 | 2017 | 2298 | 0.110 |
Why?
|
| Analgesics | 1 | 2020 | 1070 | 0.110 |
Why?
|
| Young Adult | 14 | 2024 | 60045 | 0.110 |
Why?
|
| Glucose | 2 | 2024 | 4355 | 0.110 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 740 | 0.110 |
Why?
|
| Comorbidity | 6 | 2019 | 10601 | 0.110 |
Why?
|
| Health Care Costs | 3 | 2022 | 3265 | 0.110 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2016 | 726 | 0.110 |
Why?
|
| Prostate | 3 | 2023 | 1781 | 0.110 |
Why?
|
| Interview, Psychological | 1 | 2016 | 812 | 0.110 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 627 | 0.110 |
Why?
|
| Self Report | 2 | 2022 | 3771 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 3 | 2016 | 363 | 0.100 |
Why?
|
| Telephone | 1 | 2016 | 630 | 0.100 |
Why?
|
| Cytokines | 2 | 2018 | 7449 | 0.100 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 357 | 0.100 |
Why?
|
| Limb Salvage | 2 | 2008 | 489 | 0.100 |
Why?
|
| Body Height | 2 | 2010 | 1568 | 0.100 |
Why?
|
| Vibration | 1 | 2014 | 335 | 0.100 |
Why?
|
| Models, Biological | 2 | 2011 | 9505 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2012 | 40 | 0.100 |
Why?
|
| Sexuality | 1 | 2014 | 180 | 0.100 |
Why?
|
| Models, Chemical | 1 | 2014 | 611 | 0.100 |
Why?
|
| Body Weight | 5 | 2013 | 4630 | 0.100 |
Why?
|
| Noise | 1 | 2014 | 292 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 429 | 0.100 |
Why?
|
| Heart Bypass, Right | 1 | 2012 | 75 | 0.100 |
Why?
|
| Azasteroids | 1 | 2012 | 37 | 0.100 |
Why?
|
| Alopecia | 1 | 2016 | 416 | 0.100 |
Why?
|
| Length of Stay | 5 | 2020 | 6521 | 0.100 |
Why?
|
| Diuretics | 1 | 2015 | 612 | 0.100 |
Why?
|
| Postoperative Care | 2 | 2016 | 1481 | 0.100 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 5887 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2015 | 692 | 0.100 |
Why?
|
| Blood Glucose | 4 | 2021 | 6429 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2015 | 1502 | 0.100 |
Why?
|
| Adiposity | 2 | 2012 | 1888 | 0.100 |
Why?
|
| Calcifediol | 1 | 2012 | 160 | 0.090 |
Why?
|
| Caregivers | 2 | 2021 | 2302 | 0.090 |
Why?
|
| Calcitriol | 1 | 2013 | 303 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2018 | 797 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2279 | 0.090 |
Why?
|
| Diet Surveys | 1 | 2015 | 1161 | 0.090 |
Why?
|
| Chemistry, Clinical | 1 | 2011 | 64 | 0.090 |
Why?
|
| Anabolic Agents | 1 | 2013 | 256 | 0.090 |
Why?
|
| Radius Fractures | 1 | 2017 | 514 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2018 | 874 | 0.090 |
Why?
|
| Atherosclerosis | 2 | 2018 | 3431 | 0.090 |
Why?
|
| Ankle Brachial Index | 1 | 2011 | 163 | 0.090 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 533 | 0.090 |
Why?
|
| Vitamin D Deficiency | 2 | 2012 | 1389 | 0.090 |
Why?
|
| Optometry | 1 | 2010 | 29 | 0.090 |
Why?
|
| Testis | 1 | 2013 | 783 | 0.090 |
Why?
|
| Executive Function | 2 | 2018 | 1402 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 1076 | 0.080 |
Why?
|
| Accommodation, Ocular | 1 | 2010 | 47 | 0.080 |
Why?
|
| Impotence, Vasculogenic | 1 | 2009 | 13 | 0.080 |
Why?
|
| Isoflavones | 1 | 2010 | 139 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2016 | 1107 | 0.080 |
Why?
|
| Protein Multimerization | 1 | 2014 | 980 | 0.080 |
Why?
|
| Fatigue | 2 | 2018 | 1556 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1244 | 0.080 |
Why?
|
| Trinucleotide Repeats | 1 | 2010 | 257 | 0.080 |
Why?
|
| Lung | 2 | 2018 | 10090 | 0.080 |
Why?
|
| Mexico | 1 | 2011 | 766 | 0.080 |
Why?
|
| Hypertension | 5 | 2023 | 8611 | 0.080 |
Why?
|
| Outpatients | 1 | 2017 | 1607 | 0.080 |
Why?
|
| Eyeglasses | 1 | 2010 | 138 | 0.080 |
Why?
|
| Allied Health Personnel | 1 | 2010 | 156 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2022 | 3077 | 0.080 |
Why?
|
| Family Health | 1 | 2013 | 1256 | 0.080 |
Why?
|
| Growth Hormone | 1 | 2010 | 573 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1518 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 1797 | 0.080 |
Why?
|
| Heart Ventricles | 2 | 2010 | 3839 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2017 | 9687 | 0.080 |
Why?
|
| Norwood Procedures | 1 | 2010 | 192 | 0.070 |
Why?
|
| Cluster Analysis | 4 | 2021 | 2731 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2013 | 6353 | 0.070 |
Why?
|
| Iron | 2 | 2015 | 1813 | 0.070 |
Why?
|
| Thinness | 1 | 2011 | 483 | 0.070 |
Why?
|
| Linear Models | 5 | 2019 | 5880 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2017 | 5152 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 12242 | 0.070 |
Why?
|
| Cholecalciferol | 1 | 2013 | 557 | 0.070 |
Why?
|
| Electroencephalography | 2 | 2022 | 6309 | 0.070 |
Why?
|
| Phenotype | 2 | 2023 | 16712 | 0.070 |
Why?
|
| Coronary Vessels | 2 | 2016 | 3122 | 0.070 |
Why?
|
| Bone Resorption | 1 | 2011 | 727 | 0.070 |
Why?
|
| Reproduction | 1 | 2012 | 646 | 0.070 |
Why?
|
| Hyperlipidemias | 2 | 2010 | 773 | 0.070 |
Why?
|
| Sleep | 1 | 2023 | 4796 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2008 | 159 | 0.070 |
Why?
|
| Hemoglobins | 3 | 2023 | 1532 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2021 | 2891 | 0.070 |
Why?
|
| Brazil | 1 | 2011 | 1247 | 0.070 |
Why?
|
| Poverty | 1 | 2019 | 2719 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2016 | 2131 | 0.070 |
Why?
|
| Adolescent | 15 | 2024 | 89168 | 0.070 |
Why?
|
| Population Groups | 1 | 2008 | 208 | 0.070 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 2427 | 0.070 |
Why?
|
| Work Capacity Evaluation | 1 | 2006 | 42 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2015 | 1894 | 0.070 |
Why?
|
| Hip | 1 | 2008 | 255 | 0.070 |
Why?
|
| Medicare | 2 | 2022 | 6881 | 0.070 |
Why?
|
| Physical Endurance | 1 | 2008 | 370 | 0.060 |
Why?
|
| Endocrine System | 1 | 2006 | 113 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 1337 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5308 | 0.060 |
Why?
|
| Urination Disorders | 1 | 2007 | 238 | 0.060 |
Why?
|
| Hepatocytes | 1 | 2013 | 1247 | 0.060 |
Why?
|
| Heart | 1 | 2019 | 4451 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2019 | 9382 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 849 | 0.060 |
Why?
|
| Work | 1 | 2006 | 195 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2010 | 2944 | 0.060 |
Why?
|
| Sweden | 2 | 2018 | 1382 | 0.060 |
Why?
|
| Cytosine | 1 | 2006 | 213 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14728 | 0.060 |
Why?
|
| Guanine | 1 | 2006 | 279 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2008 | 993 | 0.060 |
Why?
|
| Energy Intake | 3 | 2017 | 2141 | 0.060 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2010 | 595 | 0.060 |
Why?
|
| Hip Joint | 1 | 2011 | 1018 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2023 | 8538 | 0.060 |
Why?
|
| Injury Severity Score | 1 | 2008 | 1053 | 0.060 |
Why?
|
| Obesity | 5 | 2023 | 13065 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 1 | 2005 | 259 | 0.060 |
Why?
|
| Myocardial Infarction | 2 | 2023 | 11515 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 609 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2006 | 781 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2742 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2013 | 2422 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3708 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2023 | 52 | 0.050 |
Why?
|
| Prognosis | 3 | 2018 | 30028 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 3734 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 1209 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2010 | 3615 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2010 | 1274 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 1943 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3116 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2008 | 682 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Safety | 1 | 2007 | 1159 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2011 | 2030 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 4077 | 0.050 |
Why?
|
| Osteocalcin | 2 | 2017 | 277 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5367 | 0.050 |
Why?
|
| Metabolism | 2 | 2016 | 193 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2017 | 1585 | 0.050 |
Why?
|
| Ovariectomy | 2 | 2014 | 614 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 21156 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 5162 | 0.050 |
Why?
|
| Extremities | 2 | 2017 | 870 | 0.050 |
Why?
|
| Kidney | 1 | 2017 | 7064 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2017 | 3858 | 0.050 |
Why?
|
| Acceleration | 1 | 2022 | 189 | 0.050 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2021 | 40 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 2705 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 2145 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2011 | 1594 | 0.050 |
Why?
|
| Age Distribution | 3 | 2016 | 2881 | 0.050 |
Why?
|
| Heart Function Tests | 2 | 2012 | 318 | 0.050 |
Why?
|
| Multilevel Analysis | 1 | 2021 | 148 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2017 | 2362 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2011 | 4202 | 0.040 |
Why?
|
| Organ Size | 2 | 2017 | 2268 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 11930 | 0.040 |
Why?
|
| Adult Children | 1 | 2020 | 104 | 0.040 |
Why?
|
| Adenine | 1 | 2006 | 993 | 0.040 |
Why?
|
| Selection Bias | 1 | 2022 | 360 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2007 | 972 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2021 | 131 | 0.040 |
Why?
|
| Stroke Volume | 2 | 2012 | 5620 | 0.040 |
Why?
|
| Herpes Zoster | 1 | 2002 | 253 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2011 | 1299 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2010 | 2714 | 0.040 |
Why?
|
| Sex Factors | 3 | 2020 | 10647 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 20762 | 0.040 |
Why?
|
| Employment | 1 | 2006 | 1120 | 0.040 |
Why?
|
| Men's Health | 1 | 2020 | 75 | 0.040 |
Why?
|
| HIV Infections | 2 | 2020 | 17564 | 0.040 |
Why?
|
| Sexual Behavior | 2 | 2024 | 2200 | 0.040 |
Why?
|
| Australia | 2 | 2015 | 1264 | 0.040 |
Why?
|
| Housing for the Elderly | 1 | 2019 | 17 | 0.040 |
Why?
|
| Purines | 2 | 2013 | 614 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2023 | 646 | 0.040 |
Why?
|
| Personality Inventory | 1 | 2002 | 1019 | 0.040 |
Why?
|
| Educational Status | 1 | 2007 | 2519 | 0.040 |
Why?
|
| Collagen Type I | 2 | 2017 | 620 | 0.040 |
Why?
|
| Brain | 2 | 2017 | 27438 | 0.040 |
Why?
|
| Medical Errors | 1 | 2007 | 1263 | 0.040 |
Why?
|
| Insulin | 3 | 2018 | 6606 | 0.040 |
Why?
|
| Remote Sensing Technology | 1 | 2019 | 92 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 4816 | 0.040 |
Why?
|
| Pelvic Floor | 1 | 2019 | 138 | 0.040 |
Why?
|
| Menopause, Premature | 1 | 2019 | 124 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 157 | 0.040 |
Why?
|
| Cross-Over Studies | 3 | 2014 | 2103 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2007 | 2508 | 0.040 |
Why?
|
| Pandemics | 3 | 2023 | 8753 | 0.040 |
Why?
|
| Retirement | 1 | 2019 | 198 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 11857 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2010 | 3941 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2023 | 1021 | 0.040 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2007 | 1081 | 0.040 |
Why?
|
| Lung Volume Measurements | 1 | 2018 | 383 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 3237 | 0.040 |
Why?
|
| Vitamins | 2 | 2018 | 1638 | 0.030 |
Why?
|
| Supine Position | 1 | 2017 | 208 | 0.030 |
Why?
|
| Students, Medical | 2 | 2007 | 1962 | 0.030 |
Why?
|
| Internship and Residency | 2 | 2007 | 5952 | 0.030 |
Why?
|
| Teriparatide | 1 | 2018 | 226 | 0.030 |
Why?
|
| Temperature | 1 | 2023 | 2237 | 0.030 |
Why?
|
| Procollagen | 1 | 2017 | 189 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2017 | 505 | 0.030 |
Why?
|
| Solubility | 1 | 2018 | 1086 | 0.030 |
Why?
|
| Chromosomes, Human, X | 1 | 2018 | 321 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2000 | 527 | 0.030 |
Why?
|
| Neuralgia | 1 | 2002 | 620 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2022 | 1139 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2007 | 241 | 0.030 |
Why?
|
| Ferritins | 1 | 2018 | 601 | 0.030 |
Why?
|
| New South Wales | 1 | 2015 | 69 | 0.030 |
Why?
|
| Financing, Government | 1 | 2019 | 473 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2016 | 6035 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1364 | 0.030 |
Why?
|
| Infection Control | 1 | 2022 | 985 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2017 | 402 | 0.030 |
Why?
|
| Ankle Joint | 1 | 2019 | 447 | 0.030 |
Why?
|
| Internet | 1 | 2007 | 3123 | 0.030 |
Why?
|
| Lipids | 2 | 2018 | 3346 | 0.030 |
Why?
|
| Feedback, Sensory | 1 | 2014 | 58 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2022 | 8730 | 0.030 |
Why?
|
| Eflornithine | 1 | 2013 | 31 | 0.030 |
Why?
|
| Pain Measurement | 3 | 2017 | 3577 | 0.030 |
Why?
|
| Thiamine | 1 | 2015 | 160 | 0.030 |
Why?
|
| Phosphorus | 1 | 2015 | 336 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 1 | 2013 | 63 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 1816 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 2483 | 0.030 |
Why?
|
| Primary Health Care | 2 | 2020 | 4737 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2022 | 2865 | 0.030 |
Why?
|
| Anthropometry | 1 | 2018 | 1343 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2015 | 275 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2018 | 635 | 0.030 |
Why?
|
| beta Carotene | 1 | 2015 | 523 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2017 | 865 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2018 | 880 | 0.030 |
Why?
|
| Androstenedione | 1 | 2013 | 132 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2017 | 606 | 0.030 |
Why?
|
| Diabetes Complications | 2 | 2012 | 1322 | 0.030 |
Why?
|
| Pelvis | 1 | 2018 | 737 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2014 | 377 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 1377 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 424 | 0.030 |
Why?
|
| Movement | 1 | 2020 | 1489 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2013 | 862 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2017 | 22293 | 0.030 |
Why?
|
| Follistatin | 1 | 2013 | 138 | 0.030 |
Why?
|
| Orgasm | 1 | 2012 | 63 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2017 | 651 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 2204 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2020 | 2733 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2017 | 406 | 0.030 |
Why?
|
| Neoplasms | 2 | 2020 | 22386 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 1039 | 0.030 |
Why?
|
| Penile Erection | 1 | 2012 | 101 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2013 | 157 | 0.030 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2022 | 1489 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2017 | 568 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3438 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 3253 | 0.030 |
Why?
|
| Sebum | 1 | 2012 | 17 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 1599 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 1697 | 0.020 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 1036 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 8051 | 0.020 |
Why?
|
| Vitamin A | 1 | 2015 | 611 | 0.020 |
Why?
|
| Health Services | 1 | 2017 | 756 | 0.020 |
Why?
|
| Coitus | 1 | 2012 | 134 | 0.020 |
Why?
|
| Transferrin | 1 | 2013 | 285 | 0.020 |
Why?
|
| Trauma Centers | 2 | 2008 | 950 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2010 | 6242 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2022 | 81834 | 0.020 |
Why?
|
| Magnesium | 1 | 2015 | 816 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 937 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2024 | 3738 | 0.020 |
Why?
|
| Risk | 2 | 2017 | 9642 | 0.020 |
Why?
|
| K562 Cells | 1 | 2013 | 645 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2012 | 280 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2018 | 10125 | 0.020 |
Why?
|
| Zinc | 1 | 2015 | 677 | 0.020 |
Why?
|
| Hypophysectomy | 1 | 2010 | 114 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 2251 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 9558 | 0.020 |
Why?
|
| Peptides | 2 | 2017 | 4368 | 0.020 |
Why?
|
| Hematocrit | 1 | 2012 | 625 | 0.020 |
Why?
|
| Soybean Proteins | 1 | 2010 | 55 | 0.020 |
Why?
|
| Smoking | 2 | 2020 | 9099 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2002 | 2913 | 0.020 |
Why?
|
| Knee Joint | 1 | 2019 | 1683 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2017 | 1804 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 1439 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1892 | 0.020 |
Why?
|
| Urban Health | 1 | 2012 | 535 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2018 | 1623 | 0.020 |
Why?
|
| Urban Population | 1 | 2017 | 2047 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2024 | 3463 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 3826 | 0.020 |
Why?
|
| Ethanol | 1 | 2015 | 1334 | 0.020 |
Why?
|
| Observer Variation | 1 | 2015 | 2622 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 6537 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2012 | 892 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2010 | 466 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3906 | 0.020 |
Why?
|
| Parents | 1 | 2022 | 3596 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 384 | 0.020 |
Why?
|
| Arousal | 1 | 2014 | 1182 | 0.020 |
Why?
|
| Brain Concussion | 1 | 2019 | 1430 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2022 | 4421 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 16029 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2013 | 848 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2011 | 993 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2011 | 772 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2017 | 2696 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 840 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2008 | 520 | 0.020 |
Why?
|
| Cholesterol | 1 | 2016 | 2910 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 617 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2013 | 807 | 0.020 |
Why?
|
| Child | 5 | 2012 | 80863 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 1479 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 1833 | 0.020 |
Why?
|
| Algorithms | 2 | 2016 | 14158 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2017 | 1876 | 0.020 |
Why?
|
| Anxiety | 1 | 2020 | 4655 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 755 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3794 | 0.020 |
Why?
|
| Heart Atria | 1 | 2011 | 1361 | 0.020 |
Why?
|
| Postmenopause | 1 | 2014 | 2519 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1727 | 0.020 |
Why?
|
| California | 1 | 2009 | 1444 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3408 | 0.010 |
Why?
|
| Polypharmacy | 1 | 2007 | 307 | 0.010 |
Why?
|
| Kinetics | 1 | 2012 | 6348 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2017 | 3471 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 6527 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 681 | 0.010 |
Why?
|
| Gene Expression | 1 | 2016 | 7605 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2017 | 6410 | 0.010 |
Why?
|
| Risk Management | 1 | 2007 | 558 | 0.010 |
Why?
|
| Demography | 1 | 2008 | 1643 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1751 | 0.010 |
Why?
|
| Genotype | 1 | 2018 | 13047 | 0.010 |
Why?
|
| Proportional Hazards Models | 2 | 2009 | 12561 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2008 | 2286 | 0.010 |
Why?
|
| Knee | 1 | 2004 | 279 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 6320 | 0.010 |
Why?
|
| Heart Rate | 1 | 2014 | 4218 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4861 | 0.010 |
Why?
|
| Calcium | 1 | 2015 | 5793 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 299 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 3437 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2011 | 2119 | 0.010 |
Why?
|
| Mice | 3 | 2013 | 82045 | 0.010 |
Why?
|
| Stroke | 1 | 2023 | 9791 | 0.010 |
Why?
|
| Mass Screening | 1 | 2016 | 5455 | 0.010 |
Why?
|
| Radiography | 1 | 2011 | 6995 | 0.010 |
Why?
|
| Schools, Medical | 1 | 2007 | 881 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2007 | 1256 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2013 | 23638 | 0.010 |
Why?
|
| Social Class | 1 | 2009 | 2000 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2863 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2002 | 1007 | 0.010 |
Why?
|
| Pain | 1 | 2015 | 5096 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 4052 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 8201 | 0.010 |
Why?
|
| Capsaicin | 1 | 2000 | 235 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 7599 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2012 | 5995 | 0.010 |
Why?
|
| Forecasting | 1 | 2008 | 2950 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2000 | 681 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2000 | 517 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 12774 | 0.010 |
Why?
|
| Patient Selection | 1 | 2010 | 4266 | 0.010 |
Why?
|
| Learning | 1 | 2007 | 1762 | 0.010 |
Why?
|
| Medically Uninsured | 1 | 2002 | 841 | 0.010 |
Why?
|
| Diet | 1 | 2015 | 8098 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2007 | 2601 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2008 | 3590 | 0.010 |
Why?
|
| Animals | 3 | 2013 | 169418 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 22365 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 19041 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2012 | 4877 | 0.010 |
Why?
|
| Decision Making | 1 | 2008 | 3961 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 23839 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2006 | 2816 | 0.010 |
Why?
|
| Social Support | 1 | 2002 | 2195 | 0.010 |
Why?
|
| Health Behavior | 1 | 2002 | 2649 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 26395 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 42623 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 30179 | 0.000 |
Why?
|